Back in 2021, AstraZeneca bought Alexion Pharma in a $39 billion deal that was something of a landmark in the industry. It was thought that this acquisition would trigger all kinds of antitrust issues, especially in the light of a threatened renewal in antitrust scrutiny, and yet the deal sailed through in April last year. Now, all of the blood, sweat and tears that must have gone into making that deal happen have all proven to be worth it as the purchase of the Boston biotech hub really starts to pay off for AstraZeneca. That's because the first and only long-acting C5 complement inhibitor in gMG, Ultomiris (ravulizumab-cwvz) has gained approval in the US. Due to the purchase of Alexion by AstraZeneca last year that makes AstraZeneca the owner of the approved inhibitor. Following the successful acquisition last year, a new division was set up in the company and it's thought that this has been the driving force behind the approval.